GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Gross Profit

I-MAB (IMAB) Gross Profit : $3.86 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Gross Profit?

I-MAB's gross profit for the six months ended in Dec. 2023 was $1.12 Mil. I-MAB's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was $3.86 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. I-MAB's gross profit for the six months ended in Dec. 2023 was $1.12 Mil. I-MAB's Revenue for the six months ended in Dec. 2023 was $1.12 Mil. Therefore, I-MAB's Gross Margin % for the quarter that ended in Dec. 2023 was N/A%.

I-MAB had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage

During the past 7 years, the highest Gross Margin % of I-MAB was 112.29%. The lowest was 47.25%. And the median was 79.77%.


I-MAB Gross Profit Historical Data

The historical data trend for I-MAB's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Gross Profit Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 4.28 235.91 6.53 -35.69 3.87

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.74 3.68 -39.22 2.75 1.12

Competitive Comparison of I-MAB's Gross Profit

For the Biotechnology subindustry, I-MAB's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


I-MAB's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, I-MAB's Gross Profit distribution charts can be found below:

* The bar in red indicates where I-MAB's Gross Profit falls into.



I-MAB Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

I-MAB's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=3.872 - 0
=3.87

I-MAB's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=1.119 - 0
=1.12

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $3.86 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

I-MAB's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=1.12 / 1.119
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


I-MAB  (NAS:IMAB) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

I-MAB had a gross margin of N/A% for the quarter that ended in Dec. 2023 => No sustainable competitive advantage


I-MAB Gross Profit Related Terms

Thank you for viewing the detailed overview of I-MAB's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


I-MAB (IMAB) Business Description

Traded in Other Exchanges
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.